​Alnylam halts hemophilia drug trial due to patient death, renewing worries over safety

Alnylam Pharmaceuticals, one of the state ’s largest and most valuable biotechs, has temporarily halted a mid-stage trial of one of its experimental drugs for hemophilia after one patient died, shaving $1 billion from its market cap. Cambridge-based Alnylam (Nasdaq: ALNY) said Thursday that it had suspended the Phase 2 trial of fitusiran after a patient died of brain swelling triggered by a blood clot. The company said the death was “possibly related” to the treatment, and that it hopes to…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news